Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution

No definition available.

Name:	mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponExecution
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponLapseOfTime
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsFor
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsForPercentage
Namespace Prefix:	mrk_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentMilestonePaymentsPerProduct
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Number of Antibody Drug Conjugates

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsNumberOfAntibodyDrugConjugates
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsRefundableUpfrontPayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Royalty Percentage

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsRoyaltyPercentage
Namespace Prefix:	mrk_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds from Upfront Payment, Cash

+ References

No definition available.

+ Details

Name:	mrk_ProceedsFromUpfrontPaymentCash
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=mrk_DaiichiSankyoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_IfinatamabDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_PatritumabDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_PatritumabDeruxtecanAndRalduotatugDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_RaludotatugDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) $ in Millions	1 Months Ended	12 Months Ended
	Aug. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Oct. 31, 2023 USD ($) antibodyDrugConjugate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		$ 17,938	$ 30,531	$ 13,548
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of antibody drug conjugates obtained right and obligations \| antibodyDrugConjugate					3
Aggregate upfront payments due upon execution in collaborative arrangement					$ 4,000
Refundable upfront payments					1,000
Maximum aggregate contingent milestone payments, per product					$ 5,500
Research and development		$ 351	5,549
Royalty percentage					5.00%
Upfront cash payment	$ 170
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Ifinatamab Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Refundable upfront payments					$ 500
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Patritumab Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Refundable upfront payments					500
Aggregate upfront payments due upon lapse of time					750
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Patritumab Deruxtecan and Ralduotatug Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate upfront payments due upon lapse of time			$ 1,500
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Raludotatug Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate upfront payments due upon lapse of time					$ 750
Liable contracted portion amount of research and development expenses to incur costs for, percentage					75.00%
Liable contracted portion amount of research and development expenses to incur costs for					$ 2,000